Establishment of novel immnotheraoy using TLR3 agonist against ESCC

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K09210
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Akita University
• Principal Investigator: Sato Yusuke 秋田大学, 医学系研究科, 講師 (10431628)
• Co-Investigator(Kenkyū-buntansha): 脇田 晃行 秋田大学, 医学部附属病院, 助教 (40610803) ; 本山 悟 秋田大学, 医学系研究科, 教授 (60292372)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 食道扁平上皮癌 / Toll-like receptor / TLR3 / CXCL10 / 予後

Outline of Final Research Achievements

To elucidate the expressions and functions of Toll-like receptor 3(TLR3) in esophageal squamous cell carcinoma (ESCC), we used TLR3 ligand, polyI:C, and ARNAX, witch is specific for TLR3 in 9 ESCC lines. By treatment with polyI:C and ARNAX, proliferation of 3 ESCC lines were down-regulated. However, proliferation of 3 ESCC lines were not changed, and proliferation of remaining 3 ESCC lines were up-regulated. Based on these results, influence of polyI:C and ARNAX on ESCC proliferation was not constant.

Free Research Field

食道外科

Academic Significance and Societal Importance of the Research Achievements

polyI:CよりもよりTLR3に特異的で副作用が少ないと考えられるARNAXを使用したが食道扁平上皮癌細胞株の細胞増殖能への影響は一定ではなかった。しかしpolyI:CおよびTLR3により食道扁平上皮癌細胞株から産生されるCXCL10 mRNAは増加しており、免疫細胞がいる生体内ではケモカインであるCXCL10産生により免疫細胞が集まり抗腫瘍免疫を起こす可能性があり腫瘍縮小効果が期待できる。